COSCIENS Short Long Term Debt Total from 2010 to 2025
| CSCI Stock | 3.62 0.02 0.56% |
Short and Long Term Debt Total | First Reported 2010-12-31 | Previous Quarter 2.3 M | Current Value 2.2 M | Quarterly Volatility 125 K |
Check COSCIENS Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among COSCIENS Biopharma's main balance sheet or income statement drivers, such as Tax Provision of 88.2 K, Net Interest Income of 327.6 K or Interest Expense of 146.2 K, as well as many indicators such as Price To Sales Ratio of 0.74, Dividend Yield of 0.0 or PTB Ratio of 0.52. COSCIENS financial statements analysis is a perfect complement when working with COSCIENS Biopharma Valuation or Volatility modules.
COSCIENS | Short Long Term Debt Total | Build AI portfolio with COSCIENS Stock |
Latest COSCIENS Biopharma's Short Long Term Debt Total Growth Pattern
Below is the plot of the Short Long Term Debt Total of COSCIENS Biopharma over the last few years. It is COSCIENS Biopharma's Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in COSCIENS Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Short Long Term Debt Total | 10 Years Trend |
|
Short Long Term Debt Total |
| Timeline |
COSCIENS Short Long Term Debt Total Regression Statistics
| Arithmetic Mean | 2,067,033 | |
| Geometric Mean | 2,063,275 | |
| Coefficient Of Variation | 6.05 | |
| Mean Deviation | 63,291 | |
| Median | 2,077,549 | |
| Standard Deviation | 124,956 | |
| Sample Variance | 15.6B | |
| Range | 612K | |
| R-Value | (0.03) | |
| Mean Square Error | 16.7B | |
| R-Squared | 0 | |
| Significance | 0.90 | |
| Slope | (858.37) | |
| Total Sum of Squares | 234.2B |
COSCIENS Short Long Term Debt Total History
About COSCIENS Biopharma Financial Statements
Investors use fundamental indicators, such as COSCIENS Biopharma's Short Long Term Debt Total, to determine how well the company is positioned to perform in the future. Although COSCIENS Biopharma's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 2.3 M | 2.2 M |
Currently Active Assets on Macroaxis
When determining whether COSCIENS Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of COSCIENS Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cosciens Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cosciens Biopharma Stock:Check out the analysis of COSCIENS Biopharma Correlation against competitors. For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of COSCIENS Biopharma. If investors know COSCIENS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.21) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
The market value of COSCIENS Biopharma is measured differently than its book value, which is the value of COSCIENS that is recorded on the company's balance sheet. Investors also form their own opinion of COSCIENS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is COSCIENS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because COSCIENS Biopharma's market value can be influenced by many factors that don't directly affect COSCIENS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between COSCIENS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if COSCIENS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, COSCIENS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.